Syphilis serology and HIV infection in Harare, Zimbabwe

Lovemore Gwanzura, Ahmed Latif, Mary Bassett, Rhoderick Machekano, David A Katzenstein, Peter R Mason

Introduction
A significant epidemiological association between infection with *Treponema pallidum* (syphilis) and infection with the human immunodeficiency virus (HIV) has been demonstrated in many studies in Africa and elsewhere. While both infections show similarity in the mode of transmission, ulcerative genital lesions contain large numbers of both CD4 and CD8 lymphocytes, and so may be a site of both HIV shedding and invasion. Interventions directed towards reducing the incidence of syphilis and other sexually transmissible infections are regarded as important strategies in HIV control, and information on the epidemiology of syphilis is necessary for the design of such programmes.

Atypical clinical presentation of syphilis has been described in patients with HIV, and abnormalities are more pronounced in patients with low CD4 cell counts. Because immune responses to *T. pallidum* are primarily cell mediated, the loss of cellular immunity may intensify the ability of the organism to multiply in a variety of tissues, resulting in persistent genital ulceration and an increased likelihood of symptoms of secondary syphilis, gummatous lesions, and rapid progression to neurosyphilis. The laboratory diagnosis of syphilis relies on serological assays which include non-treponemal screening tests and treponemal confirmatory tests. Non-treponemal tests such as VDRL (Venereal Disease Reference Laboratory) and RPR (rapid plasma reagin) detect antibodies to a cardiolipin-lecithin-cholesterol antigen, and they are positive in >99% of cases of secondary syphilis. They are, however, much less sensitive in detecting early, latent, or late syphilis. Specific treponemal tests include haemagglutination, fluorescent antibody, and enzyme immunoassays, with TPHA (T. pallidum haemagglutination assay), and FTA-Abs (fluorescent treponemal antibody using absorbed sera) being the most frequently used of these. Biological false positive (BFP) reactions are defined as a rise in titre to non-treponemal reagin antigens while specific treponemal tests remain negative. Transient BFP may occur in a variety of acute viral and other infections and chronic BFP reactions may be detected in non-infectious conditions such as lupus erythematosus and malignancy and in injecting drug users (IDU). The BFP rate may be as high as 50% in selected populations, though it is expected to be of the order of 1–2% in a healthy population. The reliability of treponemal antibody tests in syphilis is regarded as being very high, with <1% false positive reactions.

Objective: To determine the reliability of serological tests in detecting syphilis in a factory worker cohort and examine the impact of concurrent HIV infection on serological tests for syphilis.

Method: Reactions to non-treponemal and treponemal antigens were tested using sera from a cohort of 3401 factory workers in Harare, Zimbabwe. The participants consented to regular testing for syphilis, by VDRL, and HIV using two ELISAs. All sera from men who were VDRL positive, and a random sample of VDRL negative sera, were tested by RPR, TPHA, and where appropriate FTA-Abs. From the results, men were defined as having no syphilis, active syphilis, incident syphilis, historic syphilis, or giving biological false positive reactions.

Results: 709 sera were examined from 580 men. There were 78 cases of active syphilis in the cohort, giving a prevalence of 2.3%, and the seroconversion was 0.25 per 100 person years of follow-up. The prevalence of HIV in the cohort was 19.8%. There was a strong association between syphilis, whether active, incident or historic, and HIV seropositivity. With both HIV positive and negative sera the negative predictive values of VDRL and RPR were >99.0% while the positive predictive value for VDRL (30%) was lower than for RPR (39%). Biological false positive reactions were detected in 0.5% of the cohort, with in most cases a transient rise in VDRL titres up to <1/16. Higher false positive titres occurred in five men, each of whom was HIV positive.

Conclusions: The VDRL is reliable in detecting possible cases of syphilis even in a community with a high prevalence of heterosexually transmitted HIV. There is need, however, for confirmatory tests. The prevalence of syphilis in this cohort is very low in comparison with other countries in southern Africa, but is consistent with recent data from Harare. Despite a strong association between syphilis and HIV it was clear that syphilis could not be counted as a major factor fuelling the HIV epidemic in Zimbabwe.

Keywords: syphilis; serodiagnosis; HIV; *Treponema pallidum*; Zimbabwe
positives, even among sera from patients with lupus or from IDU. The low cost and simplicity of non-treponemal serology tests, however, means they are frequently used for screening large numbers of sera. Positive sera are then subjected to specific treponemal tests to distinguish BFP reactions from true syphilis infection.

The reliability of non-treponemal tests in detecting syphilis in HIV positive individuals is uncertain. A high prevalence of both BFP and false negative reactions has been recorded while recent studies have indicated that at least some apparent BFP may in fact represent false negative treponemal serology. Most of the studies on syphilis serology in HIV positives have used populations that include IDU and, as noted above, such people are at high risk of giving chronic BFP reactions.

In order to examine the impact of HIV infection on serological responses to syphilis and to provide data on epidemiology of syphilis, we examined sera collected from factory workers in Harare, Zimbabwe under the Zimbabwe AIDS Prevention Project (ZAPP).

Materials and methods

ZAPP COHORT

The ZAPP enrolled a rolling cohort of 3401, mostly male, factory workers in Harare, Zimbabwe, between 1993 and 1996. The participants gave consent to regular serological testing for HIV, syphilis, and hepatitis B infection, and provided demographic and behavioural information. The details of the cohort and risk factors for HIV seropositivity have been given elsewhere. The protocol was approved by the Medical Research Council of Zimbabwe and by institutional review boards of the University of Zimbabwe and Stanford University.

SERUM SPECIMENS

Clotted blood samples were collected at enrolment into the cohort, and thereafter blood was collected at about 4 monthly intervals during the programme. Blood samples were centrifuged, and sera were stored in aliquots of about 0.5 ml. One aliquot was used for serological testing at the time of sample preparation, and others were stored at -20°C for follow up studies. Aliquots were stored in sequence, using laboratory, ZAPP identification, and date labels to ensure accurate and efficient retrieval.

SEROLOGICAL TESTING

Initial screening of sera for antibodies to HIV-1 and HIV-2 and syphilis was carried out at the National Blood Transfusion Service (NBTS) laboratories in Harare, using two separate HIV ELISAs (Abbott Labs, USA; Behring, Germany), and a modified VDRL assay using carbon antigen (Cambridge Biotech, UK). The assays were carried out using a standard operating procedure, and the results were stored on the ZAPP database. The NBTS is a national testing and training centre for identification of safe blood, and has a high standard of laboratory expertise. They subscribe to the Zimbabwe National Quality Assurance Programme (ZINQAP) for medical laboratories.

SERUM SELECTION

For the purposes of this study, the ZAPP database was screened to identify the following serum samples:

(a) One aliquot from every bleed for members of the cohort who gave a positive VDRL reaction at any time, whether at enrolment or during follow up. This ensured that we identified all cases of active syphilis, prevalent and incident, in the study cohort.

(b) One enrolment serum aliquot from members of the cohort who were consistently VDRL negative throughout the programme. The sera were used to determine antibodies to specific treponemal antigens in VDRL and RPR negative sera, and they were selected from the ZAPP database to include about equal numbers of HIV positives and HIV negatives. Financial constraints meant that the whole cohort sample could not be examined in this way.

(c) Aliquots of follow up sera from all members of the cohort who, although VDRL seronegative, were positive by any other test for antibodies to syphilis as described below. Sera that were VDRL negative but positive by a treponemal test may have resulted from either acute syphilis infection or old inactive syphilis. These were distinguished on the basis of examination of the follow up sera.

SYPHILIS SEROLOGY AND DIAGNOSIS

The sera collected in this study were retested for antibodies to syphilis using the following protocol. The previously obtained VDRL result was recorded and the sera were then tested using RPR (ImmuTrep RPR, Omega Diagnostics). If the RPR result was concordant with the VDRL result, the sera were tested by TPHA only (ImmuTrep TPHA, Omega Diagnostics). If there was a difference between the results of the two non-treponemal tests, or if there was a difference in results using enrolment and follow up sera (that is, seroconversion or transient BFP) the sera were tested with both TPHA and FTA-Abs (Wellcome Labs). In each case the test was carried out under the supervision of a qualified medical technologist and the manufacturer’s methods and interpretation of results were closely followed. For RPR sera were tested undiluted, and for TPHA sera were tested at a dilution of 1/80 in the diluent supplied by the manufacturer. In addition to the kit controls, known positive and negative sera from other studies in Zimbabwe were used as internal controls. A randomly selected proportion of the sera (n=85, 12%) was also tested independently by the laboratory of the Biomedical Research and Training Institute as an external quality control. The BRTI laboratory also subscribes to the ZINQAP in serology. There were no differences in test results.

On the basis of these results, members of the cohort were identified as having:
Table 1 Non-treponemal serologies in the factory worker cohort

<table>
<thead>
<tr>
<th>Table 1 Non-treponemal serologies in the factory worker cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sphyllis status</strong></td>
</tr>
<tr>
<td>---------------------</td>
</tr>
<tr>
<td><strong>VDRL</strong></td>
</tr>
<tr>
<td>Pos</td>
</tr>
<tr>
<td>Neg</td>
</tr>
<tr>
<td><strong>VDRL sensitivity</strong></td>
</tr>
<tr>
<td><strong>VDRL specificity</strong></td>
</tr>
<tr>
<td><strong>VDRL-PPV</strong></td>
</tr>
<tr>
<td><strong>VDRL-NPV</strong></td>
</tr>
<tr>
<td><strong>VDRL specificity</strong></td>
</tr>
<tr>
<td><strong>VDRL sensitivity</strong></td>
</tr>
<tr>
<td><strong>VDRL specificity</strong></td>
</tr>
<tr>
<td><strong>VDRL-PPV</strong></td>
</tr>
<tr>
<td><strong>VDRL-NPV</strong></td>
</tr>
</tbody>
</table>

*Sera from participants with incident or historic syphilis were excluded.

(a) No sphyllis if all tests were negative. If only a non-treponemal test was positive, the result was regarded as a BFP reaction. In such cases the VDRL and RPR titre were determined using doubling dilutions of serum as described by the manufacturers.

(b) Active sphyllis if the enrolment serum was positive for at least one non-treponemal and one treponemal test.

(c) Incident sphyllis if the enrolment serum showed no sphyllis while any of the follow up sera showed active sphyllis, as defined in (b) above.

(d) Historic sphyllis if both enrolment and follow up sera gave a positive reaction in at least one treponemal test, and a negative reaction with both non-treponemal tests.

These definitions, rather than the classic terminology of primary, latent, and late sphyllis, were used because they are based on serological criteria only rather than the more usual combination of both serological and clinical findings. All participants with active or incident sphyllis were offered treatment with a single dose of 2.4 million units of benzathine penicillin (incident cases) or with three doses each of 2.4 million units of benzathine penicillin administered at weekly intervals (prevalent cases). This treatment is in accordance with national guidelines. Men identified with sphyllis were encouraged to bring their sexual partner(s) for testing and treatment.

**DATA ANALYSIS**

The sensitivity and specificity of VDRL and RPR for sphyllis screening were determined for both HIV positive and HIV negative sera. The sensitivity and specificity data were then applied to the cohort as a whole.

**Results**

**RELIABILITY OF VDRL AS A SCREEN FOR SYPHILIS**

A total of 709 sera were examined from 580 participants. There were 483 (83%) participants with no evidence of sphyllis, 78 (13%) with serological evidence of active sphyllis, 13 (2%) with incident sphyllis, and six (1%) with historic sphyllis. Because the sampling method collected all sera that were VDRL positive, and the negative predictive value of VDRL is very high (see below), the prevalence of active sphyllis in the ZAPP cohort was 78/3401 (2.3%). The true prevalence of historic sphyllis may be higher than estimated here because we only examined sera from about 12% of the whole cohort using the treponemal tests that detect past infections. The prevalence of HIV at enrolment was 49% (38/78) in men with active sphyllis, 62% (8/13) in men with incident sphyllis, and 67% (4/6) in men with historic sphyllis. The prevalence of HIV in men with no evidence of sphyllis (42%, 195/467) was skewed by the selection process which specifically required about equal numbers of HIV positive and HIV negative sera. The enrolment HIV prevalence in the cohort as a whole was 19.8%. HIV seropositivity was highly associated with serological evidence of sphyllis, whether active, incident, or historic, with 50/97 (51.5%) such men being HIV positive compared with 610/3304 (18.5%) men who had no evidence of sphyllis ($\chi^2$ 5.9, p<0.0001).

The diagnosis of no sphyllis and active sphyllis reached above was used as the “gold standard” to determine the sensitivity and specificity of screening tests for sphyllis. This analysis included results from sphyllis screening of all sera including BFPs. Cases of incident and historic sphyllis were, however, excluded from this analysis, since these were by definition VDRL negative on enrolment. The results (table 1) indicate the RPR to have a slightly higher sensitivity and specificity than the VDRL. There was no difference in sensitivity or specificity when analysed separately by HIV serostatus (data not shown). Since these tests detect antibodies to a disease state, rather than a specific organism, the positive and negative predictive values are of greater importance. Assuming the sphyllis prevalence in the whole cohort to be 2.3%, the VDRL had a positive predictive value of only 29.5% (75/254) compared with 39.1% (77/197) for RPR. The negative predictive values for both tests were >99.9% under these conditions.

If TPHA had been used as a screen, active sphyllis would have been detected in 164/166 (99%) men who had active sphyllis by our definition, the other two sera being positive by FTA-Abs but not by TPHA. Each TPHA positive serum that was tested was also positive by FTA-Abs. With eight (62%) incident participants the TPHA became positive at the same time as FTA-Abs, while in five (38%) cases the FTA-Abs became positive before the TPHA. With four (31%) participants, all HIV positive, the VDRL was positive before TPHA, and in two cases also before FTA-Abs.

**BIOLGICAL FALSE POSITIVE REACTIONS**

Twenty serum samples from 16 participants gave non-treponemal false positive reactions, 16 with VDRL only, one with RPR only, and three with both. Of these 20 BFP, 15 were at low VDRL titre (1/8 or less) while three were at a titre of 1/16 and two were at a titre of 1/32. These last five sera were all from HIV seropositive men. Sera obtained subsequent to the BFP sample were available from 14 participants, and in all except one case both VDRL and RPR as well as treponemal tests were negative. In one case, the serum was positive by both VDRL and RPR, but negative by treponemal tests at enrolment, and the subsequent sample was VDRL positive but RPR.
negative. The next and each subsequent sample were negative for syphilis by all serological tests. Nine of the 16 BFP samples were from HIV positive men.

Discussion
The primary method for detecting suspected active syphilis in the cohort was a positive VDRL reaction. Because VDRL had a very high negative predictive value (>99.9%), we can be reasonably certain that all suspect cases in the cohort were in fact identified, though specific treponemal tests were necessary to establish true infections. The syphilis serology data from the subsample can therefore be applied to the cohort as a whole with a high degree of confidence. On this basis, the enrolment prevalence of syphilis in this cohort was 2.3%. This is substantially lower than Tanzania (6%), Ethiopia (9%), and Mozambique (12%)1-4 though the population in our cohort may not be directly comparable. The incidence of syphilis in this community was also very low (0.25 new cases of syphilis per 100 person years). During the past decade a very low (0.25 new cases of syphilis per 100 person years). Since 1995, however, the incidence of syphilis remained at this level.15

We thank ZAPP staff for assistance in blood and data collections, and the National Blood Transfusion Service for identifying the sera used. The ZAPP is supported by US Public Health Service Award No AI 33808-02. Contributors: L. Gwanzura was responsible for the selection and laboratory testing of samples and assisted with data analysis and write up; A. Lati and D. A. Katzenstein are principal clinical researchers in ZAPP and assisted in study design and analysis; M. Basset is director of ZAPP in Harare and assisted in writing the article; R. Machakono supplied statistical advice in serum selection and analysis of data; and P. R. Mason supervised the study design and analysis, and was responsible for writing the article.

2 Locke GP, Bagg RM, Jaffe HW, et al. HIV infection is prevalent.
Joint Meeting of MSSVD and the ASTDA

3–7 May 2000, Baltimore Marriott Inner Harbor Hotel, Baltimore, Maryland, USA

To mark the unique nature of the millennial year, for the first time in its 78 year history the Medical Society for the Study of Venereal Diseases will hold its Spring Meeting jointly with the American Sexually Transmitted Disease Association (President, Professor Julius Schacter). Our local host will be Professor Jonathan Zenilman of Johns Hopkins Medical School. The scientific programme will consist of plenary lectures and round table discussions, delivered by world authorities. There will also be oral and poster presentations of original work.

Further mailings will follow to MSSVD and ASTDA members. People who do not belong to either of these organisations and who would like to receive further information should contact: Dr Keith Radcliffe, Honorary Assistant Secretary, MSSVD (fax: +44 (0) 121-237 5729; email: k.w.radcliffe@bham.ac.uk).